倍他乐克联合胺碘酮、门冬氨酸钾镁对急性心肌梗塞早期并发室颤的救治

目的:评价静脉应用倍他乐克联合胺碘酮、门冬氨酸钾镁治疗急性心肌梗塞(AMI)早期并发恶性心律失常(室颤)临床疗效。方法:选择2004年1月～2005年1月住院的6例AMI患者,在常规治疗的基础上,反复电除颤室颤不能得以控制,随即应用倍他乐克5ml分3次静注,同时静点胺碘酮450mg 5%葡萄糖注射液(15滴/min),门冬氨酸钾镁4.0 5%葡萄糖注射液。结果:6例中抢救成功5例,死亡1例,存活率:83.33%。除在应用倍他乐克开始阶段2例表现为一过性低血压,1例因心功不全猝死,未见心功能恶化及致心律失常作用。结论:急性心肌梗塞早期静脉应用倍他乐克联合胺碘酮,门冬氨酸钾镁能够有效控制室颤,降低死亡率。

Effect of betaloc and amiodalone intravenous injection in patients with acute myocardium infarction early complicated ventricular fibrillation

Objective:To study the effect of betaloc and amiodalone intravenous injection in patients with acute myocardium infarction(AMI)early complicated ventricular fibrillation(VF).Methods:The 6 AMI patients complicated VF were no controled VF by routine therapy and repeated electrical defibrillation.Then they were treated with betaloc,amiodalone and potassium magnesium aspartate intravenous injection.Results:The 5 AMI patients complicated VF(83.33%)were survival after treat.Except one patient died because heart failure there was no severity adverse reaction.Conclusion:The betaloc,amiodalone and potassium magnesium aspartate intravenous injection may control ventricular fibrillation and decrease mortality in early AMI patients complicated ventricular fibrillation.